FDA warns on compounded GLP-1 weight loss drugs

The Food and Drug Administration is taking a firm stance against the marketing practices of various telehealth companies. Last month, federal regulators issued 25 warning letters to organizations accused of making misleading claims about compounded versions of popular weight loss drugs like Ozempic.

Compounded medications are customized by pharmacies for individual patients, which can include changes to potency or administration methods. However, these versions lack the rigorous safety and efficacy testing required for FDA-approved products. Health experts emphasize that consumers often turn to these alternatives due to the high cost of brand-name GLP-1 drugs, which can exceed $1,000 per month without insurance coverage.

Medical professionals advise patients to avoid these unregulated alternatives. Stanford Medicine expert Dr. Michael Blyumin notes that patients often assume approved medications are unaffordable, yet many are unaware of assistance options available to them. Without federal oversight, the risks associated with compounded drugs remain a point of concern for regulators and doctors alike.

Patients are encouraged to obtain prescriptions through established medical channels and ensure their medications are sourced from licensed pharmacies. The FDA maintains that compounded drugs should be reserved for specific patient needs that standard approved treatments cannot address, rather than serving as a primary substitute during supply shortages.